Clinical Utility of 18F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy
Movement Disorders2021Vol. 36(10), pp. 2314–2323
Citations Over TimeTop 10% of 2021 papers
Ling Li, Fengtao Liu, Ming Li, Jiaying Lu, Yi‐Min Sun, Xiaoniu Liang, Weiqi Bao, Qi‐Si Chen, Xinyi Li, Xinyue Zhou, Yihui Guan, Jian Wu, Tzu‐Chen Yen, Ming‐Kuei Jang, Jianfeng Luo, Jian Wang, Chuantao Zuo, the Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI)
Abstract
18 F-APN-1607 PET imaging holds promise for the diagnosis, differential diagnosis, and assessment of disease severity in patients with PSP. © 2021 International Parkinson and Movement Disorder Society.
Related Papers
- → Glucocerebrosidase mutations are an important risk factor for Lewy body disorders(2006)227 cited
- → ɑ-Synuclein strains and seeding in Parkinson’s disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences(2018)121 cited
- → Progressive supranuclear palsy phenotype mimicking synucleinopathies(2013)6 cited
- → Atypical Parkinsonian Syndromes: Tauopathies(2017)
- → Atypical Parkinsonian Syndromes: Tauopathies(2017)